Biomaven, I like to look at outcomes as probabilities.
AP32788 is an investigational oral tyrosine kinase inhibitor (TKI) of activating mutations in EGFR and HER2. The molecule was designed to address the unmet need in patients with non-small cell lung cancer (NSCLC) driven by exon 20 insertion mutations in EGFR and HER2, Knowing that '788 is targeting two mutations, EGFR and HER2, driven by exon 20 insertion mutations, doesn't that reduce the chances of early approval after a phase 2 trial as this will be quite complex? Remember, Ariad targeted EGFR and ALK+, and we all know what happened in that trial. Especially after, as Tim Clackson has stated, "others have tried and failed" with the target for '788. This is a difficult area it appears.. So, on a scale of 1 to 10, with ten being a sure thing, how would you rate the probability of approval after the completion of the phases II trial of '788? |
